Clinical management of seizures in patients with low-grade glioma

Seminars in Radiation Oncology

Volumn 25, Issue 3, 2015, Pages 219-224

  Piotrowski, Anna F ^a   Blakeley, Jaishri ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; VALPROIC ACID; PIRACETAM; TRIAZINE DERIVATIVE;

ARTICLE; CANCER SURGERY; COGNITION; DEVICE THERAPY; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; GLIOMA; HUMAN; INCIDENCE; INTRACTABLE EPILEPSY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SURGICAL APPROACH; SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; BRAIN TUMOR; COMPLICATION; SEIZURES;

ANTICONVULSANTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; PIRACETAM; SEIZURES; TRIAZINES;

EID: 84943184665     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.02.009     Document Type: Review

References (32)

1. Pace A, Bove L, Innocenti P, et al: Epilepsy and gliomas: Incidence and treatment in 119 patients. J Exp Clin Cancer Res 17(4):479-482, 1998
2. Kerkhof M, Vecht CJ: Seizure characteristics and prognostic factors of gliomas. Epilepsia 54(Suppl 9):12-17, 2013
3. Iuchi T, Hasegawa Y, Kawasaki K, et al: Epilepsy in patients with gliomas: Incidence and control of seizures. J Clin Neurosci 22(1):87-91, 2015
4. Berg AT, Berkovic SF, Brodie MJ, et al: Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51(4): 676-685, 2010
5. Bien CG, Elger CE: Epilepsia partialis continua: Semiology and differential diagnosis. Epileptic Disord 10(1):3-7, 2008
6. Ruda R, Bello L, Duffau H, et al: Seizures in low-grade gliomas: Natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14 (Suppl 4):55-64, 2012
7. Liigant A, Haldre S, Oun A, et al: Seizure disorders in patients with brain tumors. Eur Neurol 45(1):46-51, 2001
8. DeAngelis LM: Brain tumors. N Engl J Med 344(2):114-123, 2001
9. Glantz MJ, Cole BF, Forsyth PA, et al: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54(10):1886-1893, 2000
10. Chang BS, Lowenstein DH: Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 60(1):10-16, 2003
11. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al: Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev(2):CD004424, 2008
12. Englot DJ, Berger MS, Barbaro NM, Chang EF: Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg 115(2):240-244, 2011
13. van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366(9490):985-990, 2005
14. Ruda R, Magliola U, Bertero L, et al: Seizure control following radiotherapy in patients with diffuse gliomas: A retrospective study. Neuro Oncol 15 (12):1739-1749, 2013
15. Koekkoek JA, Dirven L, Heimans JJ, et al: Seizure reduction in a low-grade glioma: More than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. http://dx.doi.org/10.1136/jnnp-2014-308136
16. Sherman JH, Moldovan K, Yeoh HK, et al: Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 114(6):1617-1621, 2011
17. Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14(12):1715-1721, 2003
18. Glauser T, Ben-Menachem E, Bourgeois B, et al: Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3):551-563, 2013
19. Rossetti AO, Jeckelmann S, Novy J, et al: Levetiracetam and pregabalin or antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro Oncol 16(4):584-588, 2014
20. Maschio M, Dinapoli L, Sperati F, et al: Levetiracetam monotherapy in patients with brain tumor-related epilepsy: Seizure control, safety, and quality of life. J Neurooncol 104(1):205-214, 2011
21. Lim DA, Tarapore P, Chang E, et al: Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study. J Neurooncol 93(3):349-354, 2009
22. Kerkhof M, Dielemans JC, van Breemen MS, et al: Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967, 2013
23. Weller M, Gorlia T, Cairncross JG, et al: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77(12):1156-1164, 2011
24. Novy J, Stupp R, Rossetti AO: Pregabalin in patients with primary brain tumors and seizures: A preliminary observation. Clin Neurol Neurosurg 111(2):171-173, 2009
25. Vecht CJ, Kerkhof M, Duran-Pena A: Seizure prognosis in brain tumors: New insights and evidence-based management. Oncologist 19(7): 751-759, 2014
26. Callaghan B, Schlesinger M, Rodemer W, et al: Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 52(3):619-626, 2011
27. Patel KS, Moussazadeh N, Doyle WK, et al: Efficacy of vagus nerve stimulation in brain tumor-associated intractable epilepsy and the importance of tumor stability. J Neurosurg 119(2):520-525, 2013
28. Reiger J, Bahr O, Maurer GD, et al: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44(6):1843-1852, 2014
29. Champ CE, Palmer JD, Volek JS, et al: Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 117(1):125-131, 2014
30. Seyfried TN, Flores R, Poff AM, et al: Metabolic therapy: A new paradigm for managing malignant brain cancer. Cancer Lett 356(2 Pt A):289-300, 2015
31. Shields LB, Choucair AK: Management of low-grade gliomas: A review of patient-perceived quality of life and neurocognitive outcome. World Neurosurg 82(1-2):e299-e309, 2014
32. Klein M, Engelberts NH, van der Ploeg HM, et al: Epilepsy in low-grade gliomas: The impact on cognitive function and quality of life. Ann Neurol 54(4):514-520, 2003